David J. Arthur
Chief Executive Officer
Mr. Arthur is a Life Sciences Executive with 25+ years of experience building and leading medical and marketing organizations in product development; launching and managing pharmaceutical and device brands. Additionally David has spent 20+ years with Eli Lilly and Boehringer-Ingelheim in Executive roles and managing product and business development for US business, global commercialization and European regional marketing and financial planning/analysis.
Mr. Arthur earned a BS in Chemical Engineering from North Carolina State University, a Masters of Business Administration from the Duke University Fuqua School of Business, is a licensed Professional Engineer and Six Sigma Green Belt.
Chief Financial Officer
Mr. Jordan is an accomplished life sciences professional with more than 25 years of investment banking and corporate experience in negotiating strategic corporate alliances, securing international licensing agreements, building national sales teams, and contributing to successful product development, approval and launch. Prior to joining Salarius, Scott was an investment banker with Healthios Capital Markets and employed in business development and commercialization roles with NeoPharm, Akorn Ophthalmics, and Abbot Laboratories
Mr. Jordan earned a BA from Michigan State University, Masters of Business Administration from Kellstadt Graduate School of Management (DePaul).
Sunil Sharma, MD, FACP
Chief Medical Officer
Dr. Sharma is the Jon and Karen Huntsman Presidential Professor for Cancer Research, Deputy Center Director, at the Huntsman Cancer Institute at the University of Utah. Dr. Sharma has conducted over 150 clinical trials over the past 15 years. Dr. Sharma started the G/I oncology investigational program at the Nevada Cancer Institute in Las Vegas and was in charge of several new drugs and their development with Novartis. Dr. Sharma has also worked at Sloan Kettering Memorial Hospital, one of the most prestigious cancer hospitals in the world. Dr. Sharma is a fellow of Dr. Daniel Van Hoff, who is often considered to be the most influential physician in oncology drug development of the last 30 years.
John Walling, Ph.D.
VP Chemistry, Manufacturing & Control
Dr. Walling has over 30 years of CMC experience in the pharmaceutical industry. Prior to joining Salarius, John was Vice President of Quality Operations for Reata Pharmaceuticals where for over 10 years he was responsible for the organization of CMC functions. Prior to that assignment, John held positions of increasing responsibility with Abbott Laboratories, Cambrex, ILEX Oncology and Phanstiehl Labratories. He holds a PhD in organic Chemistry with an emphasis on natural products synthesis
Jeff Larson, Ph.D.
VP NonClinical Development
Dr. Larson joined Salarius after a highly productive 24+ year career that included the role Vice President of BioAlliance, a nonprofit association leading life science companies in the State of Texas, where he provided a wide array of consulting services on preclinical research and development for a number of leading life science companies. Before Texas BioAlliance, Dr. Larson was a successful independent consultant providing preclinical contracting services, toxicology consulting, and litigation expert testimony. Dr. Larson has also led preclinincal development, including toxicology and pharmacokinetics, across a number of companies including; NexBio (Asun), Tanox, Sierra Biomedical (a Charles River Laboratories company), Aronex Pharmaceuticals, and Allergan.
Raffaella Soldi, Ph.D.
Director of Biology
Dr. Soldi joined Salarius as Director of Biology in 2016 and brings 25 years of translational medicine experience in preclinical and clinical development. Before joining the Salarius team she was a Sr. Research Associate at the Hunstsman Cancer Institute. Dr. Soldi received her BS in Biology at the University of Turin, Italy, and also received her PhD in Biochemistry and Cellular Biotechnology from the University of Turin, Italy.